Other News To Note

BrainStorm Cell Therapeutics Inc., of New York, inked a deal with PharmaNet LLC, of Princeton, N.J., to assist in developing the protocol and investigational new drug application file for amyotrophic lateral sclerosis (ALS) trials involving the NurOwn technology. NurOwn is based on the use of adult human mesenchymal stem cells and has orphan drug designation in ALS.